Drugmakers have welcomed the European Commission’s commitment to a “competitiveness check,” related to the legislative environment in the region.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has urged the EC to act quickly to deliver a full assessment of proposed pharmaceutical legislation on European competitiveness.
Director general Nathalie Moll said the trade body supported the communication on competitiveness, adding: “For legislation that will shape our health, science, jobs and growth for the next 20 to 30 years, it is deeply concerning that no complete competitiveness check has yet been made.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze